OR WAIT null SECS
Massive Bio and Asklepieia will utilize their technologies to provide oncologists and patients access to clinical trials, personalized cancer treatments, and reports on adequate therapies. Plans are underway for future collaborations with BeStrong and Open Health Alliance.
Cagatay M. Culcuoglu, COO, CTO, and co-founder of Massive Bio, expressed his optimism about these alliances. "Our collaboration with Asklepieia combines precision medicine with AI-driven clinical trial matching, speeding up the introduction of clinical trials in Greece," he said.
George Kakoulidis, CEO of Asklepieia, also emphasized the transformative potential of collaborations. "Our mission, through integrating with Massive Bio's platform, is to improve patients' quality of life and contribute to the global fight against cancer. We want to expand our partnership with Massive Bio to introduce new clinical trials and leverage technology to shorten the enrollment process leveraging Massive Bio’s global expertise," he stated.
Asklepieia will leverage its platform to identify patients who could most benefit from novel clinical trials, expanding Massive Bio's trials' reach. Concurrently, BeStrong and Open Health Alliance will provide physicians with updated clinical trial information for faster patient referrals, real-time support, and access to cancer patients or caregivers in Greece.
Massive Bio will use its AI to process patient clinical health data. Caglar Demirbag, director of international partnerships at Massive Bio, stated, "Our partnerships will improve access to cancer treatments in the region and promote diversity in clinical trial participation."
Massive Bio Partners with Asklepieia, BeStrong, and Open Health Alliance in Greece to Enhance Cancer Clinical Trial. (2023, August 2). Business Wire.